Lexicon Pharmaceuticals Inc (LXRX): “We expect that the new joint guidelines...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	229
Posts	21457
Boards Moderated	2
Alias Born	08/03/2006

BooDog

Re: None

Tuesday, 04/19/2022 6:24:27 AM

Tuesday, April 19, 2022 6:24:27 AM

“We expect that the new joint guidelines issued this weekend by the three largest cardiology societies in the United States, along with the new guidelines issued last year by the European Society of Cardiology, will support the emerging adoption of SGLT2 inhibitors as a first line treatment standard across heart failure,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer at Lexicon. “We believe that sotagliflozin’s unique mechanism offers opportunities for differentiation within the class, supported by the results from the SOLOIST-WHF study referenced in the guidelines as well as from the SCORED study, additional analyses from which were presented at the American College of Cardiology 71st Annual Scientific Sessions this weekend.”

https://marketwirenews.com/news-releases/lexicon-welcomes-new-guidelines-for-the-management-o-7753296108030739.html

Time to move out of the shadows.

Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis